9 completed, 2 recruiting, 1 active not recruiting, 1 terminated. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Completed 9, Recruiting 2, Active not recruiting 1, Terminated 1 |
Follow Racivir: new trials by email Literature Review of Racivir trials Research Report on Racivir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience DTG/3TC, Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF) - HIV Infection, Metabolic Syndrome | Phase 4 | Recruiting | Instituto Mexicano del Seguro Social | 124 | 2025-04-01 | 2025-06-26 |
| UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study Initiating daily oral PrEP during pregnancy, Already using daily oral PrEP at the time of pregnancy diagnosis, Initiating injectable PrEP during pregnancy - Pre-exposure Prophylaxis, HIV Prevention | Phase 4 | Recruiting | University of North Carolina, Chapel Hill | 621 | 2024-04-17 | 2026-05-05 |
| Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day, Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine. - HIV Infections, Fatty Liver Disease | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 63 | 2023-05-26 | 2025-07-18 |
| Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC) - HIV Infection | Phase 4 | Active not recruiting | Professor Francois Venter | 1900 | 2023-05-19 | 2025-06-05 |
| Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide Doravirine 100 Mg, Integrase strand transfer inhibitors, Tenofovir alafenamide/emtricitabine - HIV Infections | Phase 4 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 147 | 2021-07-27 | 2025-07-02 |
| Body Composition Sub-study of the D2EFT Trial Darunavir (DRV) 800 milligram (MG) Oral Tablet, Ritonavir 100 MG Oral Tablet, N(t)RTIs - HIV Infections | Phase 4 | Completed | Kirby Institute | 155 | 2019-12-05 | 2025-01-09 |
| Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV) Switch to DTG + FTC, Patient-centered monitoring - HIV-1-infection, Antiretroviral Therapy | Phase 4 | Completed | Calmy Alexandra | 186 | 2017-05-19 | 2019-08-29 |
| Renal Integrase Study Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat), Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet, Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir) - HIV | Phase 4 | Completed | St Stephens Aids Trust | 60 | 2015-03-01 | 2017-06-27 |
| Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy HAART regimen, 3TC or FTC monotherapy - HIV Disease | Phase 4 | Terminated | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 33 | 2011-03-01 | 2015-11-13 |
| Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection Entecavir with continued standard of care antiretroviral therapy, continued standard of care with tenofovir in addition to emtricitabine or lamivudine - HIV Infections, Hepatitis B | Phase 4 | Completed | University of California, San Francisco | 10 | 2008-04-01 | 2013-05-27 |
| ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg - HIV Infections | Phase 4 | Completed | Gilead Sciences | 115 | 2008-04-01 | 2011-11-21 |
| Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF) - HIV Infections | Phase 4 | Completed | Gilead Sciences | 300 | 2006-07-01 | 2008-04-10 |
| A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine Nevirapine, FTC, and Tenofovir - HIV | Phase 4 | Completed | University of Maryland, Baltimore | 54 | 2004-03-01 | 2021-11-01 |
HIV Infections (8) · Acquired Immunodeficiency Syndrome (3) · Breast Feeding (1) · Hepatitis B (1) · Metabolic Syndrome (1) · Non-alcoholic Fatty Liver Disease (1)
Gilead Sciences (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Calmy Alexandra (1) · Fundacion SEIMC-GESIDA (1) · Instituto Mexicano del Seguro Social (1) · International Maternal Pediatric Adolescent AIDS Clinical Trials Group (1) · Kirby Institute (1) · Professor Francois Venter (1) · St Stephens Aids Trust (1) · University of California, San Francisco (1) · University of Maryland, Baltimore (1) · University of North Carolina, Chapel Hill (1)
United States (5) · Puerto Rico (2) · South Africa (2) · Thailand (2) · United Kingdom (2) · Argentina (1) · Brazil (1) · India (1) · Malawi (1) · Malaysia (1) · Mexico (1) · Spain (1) · Switzerland (1) · Zimbabwe (1)
Allison L. Agwu, MD, Sc.M. (1) · Anne F Luetkemeyer, MD (1) · Cham Herath (1) · Charles E Davis, MD (1) · Fanscois Venter, PhD in Medicine (1) · Friday Saidi, MBBS, MMED (1) · Gail Matthews, MBBCh (1) · Graeme Moyle, MD, MBBS, Dip GUN (1) · John Flaherty (1) · John Koethe (1) · Robert R Redfield, MD (1)
PMID 19357529, PMID 19906624, PMID 20156091, PMID 28604824, PMID 33170863, PMID 38754068, PMID 39334032, PMID 41847923, PMID 42098649
P01HD112215 (1), U01AI068632 (1), UM1AI068636 (1)